Head and Neck Surgery RON is associated with tumor Progression in Head and Neck Squamous Cell Cancer
Tae Mi Yoon, MD (presenter); Dong Hoon Lee; Joon Kyoo Lee; Sang Chul Lim Objective: To investigate that the recepteur d'origine nantais (RON) expression is expressed in human head and neck squamous cell cancer (HNSCC) cells and to evaluate whether RON affects tumor cell behavior in head and neck cancer cell lines, thus serving as a target for molecular therapy in a preclinical model.
Method:
The protein expression of RON by immunohistochemistry and western blot analysis was investigated in human head-neck cancer tissues. To evaluate the impact of RON knock down on behavior of human head-neck cancer cell lines, invasion and migration assays using small-interfering RNA were performed. Western blot analysis was used to assess alteration in protein expression.
Results: RON positive immunoreactions were observed relative to adjacent mucosal tissue in all 28 cases, while 15 cases (53.6%) were over-expressed. RON over-expression was significantly associated with lymph node metastasis. RON protein expression was increased in cervical metastatic lymph node tissue by western blot analysis. Treatment of RON ligand, macrophage stimulating proetin (MSP) increased cell migration and invasion in human head-neck cancer cell lines (SNU 1041, PCI 50). The knockdown of RON significantly suppressed tumor cell migration, invasion. The Erk, p38 phosphorylation was reduced by knockdown of RON in PCI 50.
Conclusion: RON expression might play an important role in the progression, especially lymphatic metastasis of head and neck squamous cell cancer. Further investigations are needed to assess the potential of RON-directed molecular therapy in head and neck squamous cell cancer.
Head and Neck Surgery Synsepalum dulcificum and Varied taste Occurring Postradiation trial Parker A. Velargo, MD (presenter); Sandeep Samant, MD, FRCS
Objective: Postirradiation gustatory dysfunction (PIGD), which may cause malnutrition, is common in patients with head/neck cancer undergoing radiation therapy (XRT). Synsepalum dulcificum (miracle fruit) changes taste transduction mechanisms of certain substances. This investigation addresses whether S dulcificum can improve PIGD and result in weight augmentation in head/neck cancer patients.
Method: Sixteen patients meeting criteria were separated into 2 groups based on timing after XRT. In a double-blind randomized fashion, patients were assigned miracle fruit or placebo. A series of taste batteries/questionnaires were performed. Patients were given a 1-month supply of test substance. We measured pre-and posttrial weight.
Results: Fifty-four percent of patients subjectively reported that sweet tastes were most adversely affected by XRT; however, objectively all patients correctly identified sweet tastes while 30% of patients answered sour tastes incorrectly. The majority of patients in both groups had a positive response to sour tastes with S dulcificum when compared to placebo (not statistically significant). Weight gain was slightly greater in both groups with S dulcificum when compared to placebo (not statistically significant). Inter-group analyses did not yield significant differences.
Conclusion:
In the treatment of PIGD, S dulcificum may be an effective treatment for patients with sour dysfunction but may not be effective in augmenting weight. It appears to work similarly in irradiation patients regardless of time after radiation. A larger N may help to obtain more significant findings.
